<DOC>
	<DOCNO>NCT02897986</DOCNO>
	<brief_summary>Cancer remain first cause death due disease child adolescents despite important progress 70 % survivor present sequela . It therefore mandatory generate new preferably less toxic treatment strategy rely new anticancer agent , and/or new combination schedule administer compound . Metronomic chemotherapy ( MC ) consist administrate low dos anticancer agent daily/weekly basis . MC show safe effective way administer chemotherapy obtain anti-cancer effect anti-angiogenic pro-imune effect . Drug reposition consist use non-anticancer drug anti-cancer property unveil . Propranolol non selective beta-blocker initially use treat hypertension recently anticancer property discover . The place Betablockers anticancer agent support preclinical epidemiologic data . The investigator show use betablockers could sensitize breast cancer , angiosarcoma neuroblastoma chemotherapy vitro vivo least part via anti-angiogenic mechanism . There currently 12 clinical trial evaluate prospectively potential adult cancer none child far . The Objective determine Maximal Tolerated Dose ( MTD ) combination oral metronomic vinorelbine daily oral propranolol . This study phase I trial `` rolling six '' design dose escalation thrice weekly oral vinorelbine plus addition daily oral propranolol completion first cycle . PK analysis vinorelbine propranolol perform . Once recommend dose combination establish 4 extension cohort 9 patient added Potential biomarkers ( beta-adrenergic receptor tumour , B-tubulin isotypes tumour ) also evaluate . This provide well tolerate , oral combination patient refractory/relapsing tumour . This combination could also propose maintenance instance patient rhabdomyosarcoma neuroblastoma .</brief_summary>
	<brief_title>Study Propranolol ( HEMANGIOL® ) Oral Metronomic Vinorelbine ( NAVELBINE® ) Combination Children Teenagers With Refractory/Relapsing Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Histologically cytologically confirm malignant solid tumour refractory low grade glioma desmoids tumour . Relapsed refractory tumour least one line treatment ( patient previously treat oral IV vinorelbine weekly schedule ) Measurable target Lansky Score &gt; 70 score OMS &lt; 2 . Life expectancy &gt; 6 month . Adequate haematological function : neutrophil count ≥ 1.0 x 109/L , platelet count ≥ 75 x 109/L Creatinine &lt; 1.5X normal value age clearance &gt; 70 ml/mn/1.73 m2 Liver function : Bilirubin &lt; 3N ALAT ASAT &lt; 4 N ) . Other organ toxicity &lt; Grade 2 accord NCICTC version 4.0 No active infection Absence wash period : 21 day case previous chemotherapy target therapy ( reduced 2 week case treatment vincristine prolong 6 week case treatment nitrosurea agent ) 6 week case prior radiotherapy target lesion Peripheral neuropathy &gt; grade 2 contraindication Propranolol ( i.e . asthma , bradycardia , hypotension , decrease SF , ECGanomalies ) Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>